293 related articles for article (PubMed ID: 16847290)
21. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
22. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
24. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
Serrano-Rios M; Melchionda N; Moreno-Carretero E;
Diabet Med; 2002 Feb; 19(2):119-24. PubMed ID: 11874427
[TBL] [Abstract][Full Text] [Related]
25. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
[TBL] [Abstract][Full Text] [Related]
27. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
Tambascia MA; Geloneze B; Repetto EM; Geloneze SR; Picolo M; Magro DO
Diabetes Obes Metab; 2003 Sep; 5(5):338-44. PubMed ID: 12940872
[TBL] [Abstract][Full Text] [Related]
28. Summaries for patients. Effects of drug treatment for obesity in adolescence.
Ann Intern Med; 2006 Jul; 145(2):I16. PubMed ID: 16847286
[No Abstract] [Full Text] [Related]
29. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
[TBL] [Abstract][Full Text] [Related]
30. [The effect of sibutramine on weight loss in obese adolescents].
Franco RR; Cominato L; Damiani D
Arq Bras Endocrinol Metabol; 2014 Apr; 58(3):243-50. PubMed ID: 24863086
[TBL] [Abstract][Full Text] [Related]
31. Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study.
Wirth A; Scholze J; Sharma AM; Matiba B; Boenner G
Diabetes Obes Metab; 2006 Nov; 8(6):674-81. PubMed ID: 17026492
[TBL] [Abstract][Full Text] [Related]
32. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
[TBL] [Abstract][Full Text] [Related]
34. [Serum leptin and insulin resistance in obesity and effects of sibutramine on them].
Wu J; Lei MX; Chen HL
Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):605-7. PubMed ID: 15804071
[TBL] [Abstract][Full Text] [Related]
35. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
Tong NW; Ran XW; Li QF; Tang BD; Li R; Yang FY; Liu YP; Li XJ
Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
[TBL] [Abstract][Full Text] [Related]
36. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
37. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study.
Godoy-Matos A; Carraro L; Vieira A; Oliveira J; Guedes EP; Mattos L; Rangel C; Moreira RO; Coutinho W; Appolinario JC
J Clin Endocrinol Metab; 2005 Mar; 90(3):1460-5. PubMed ID: 15613431
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
Viner RM; Hsia Y; Tomsic T; Wong IC
Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
[TBL] [Abstract][Full Text] [Related]
39. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
40. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
